Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 177Lu-girentuximab |
Synonyms | |
Therapy Description |
177Lu-girentuximab is a radioconjugate comprising the radionuclide Lutetium-177 linked to girentuximab, a monoclonal antibody that targets G250, which delivers radiation to tumor cells and potentially results in inhibition of tumor growth (PMID: 14960657, PMID: 22980441). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
177Lu-girentuximab | 177Lu-DOTA-cG250|Lutetium Lu-177 Girentuximab | 177Lu-girentuximab is a radioconjugate comprising the radionuclide Lutetium-177 linked to girentuximab, a monoclonal antibody that targets G250, which delivers radiation to tumor cells and potentially results in inhibition of tumor growth (PMID: 14960657, PMID: 22980441). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|